Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Dendritic cell preparation for immunotherapeutic interventions.

Thomas Simon¹, Jean-François Fonteneau, Marc Grégoire

¹INSERM U892, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 01, France.

|July 20, 2010

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prenatal body fluid analysis in the evaluation of CAKUT.

Pediatric nephrology (Berlin, Germany)·2026

Same author

Risk Assessment of Delayed Graft Function in Pediatric Kidney Transplantation - a CERTAIN Research Network Analysis.

Transplant international : official journal of the European Society for Organ Transplantation·2026

Same author

Single cell and spatial sequencing analysis of cancer associated fibroblasts in the brain metastasis tumor microenvironment.

Communications biology·2026

Same author

Management of children and adolescents with failing kidney allografts-a review of current practice across Europe.

Pediatric nephrology (Berlin, Germany)·2026

Same author

Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial.

BMJ open·2025

Same author

A nonsense mutation in the PRKG2 gene in dalmatian dogs with chondrodysplasia.

PloS one·2025

Dendritic cell (DC) vaccines show promise for cancer immunotherapy but require optimized manufacturing for clinical efficacy. This review explores DC biology, clinical trials, and strategies to enhance DC-based cancer vaccination outcomes.

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Dendritic cells (DCs) are crucial for initiating immune responses.
DC-based vaccines have shown preclinical promise for cancer immunotherapy.
Clinical translation of DC vaccines has faced challenges in efficacy and manufacturing.

Purpose of the Study:

To review dendritic cell biology relevant to cancer immunotherapy.
To analyze DC-based clinical trials and their outcomes.
To identify strategies for optimizing DC vaccines for improved clinical efficacy and manufacturing.

Main Methods:

Review of existing literature on DC biology and cancer immunotherapy.
Analysis of data from completed DC-based clinical trials.
Focus on DC maturation status, preparation methods, and clinical outcomes.

More Related Videos

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Experiment Videos

Last Updated: Jun 10, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Main Results:

Preclinical success of DC vaccines has not consistently translated to clinical efficacy.
Optimizing DC maturation and manufacturing is critical for therapeutic success.
Various DC types, subtypes, and preparation methods have been explored in clinical studies.

Conclusions:

Improving DC vaccine efficacy requires optimizing DC maturation and manufacturing processes.
Further research into DC biology and clinical trial design is needed.
Enhanced strategies are necessary to improve the clinical outcomes of DC-based cancer vaccination.